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Uremic Syndromes. 
E E Bowen and RJ Coward. 
 
Abstract 
Hemolytic uremic syndrome (HUS) is major global health care issue as it is the leading cause of acute 
kidney injury in children. It is a triad of acute kidney injury, microangiopathic hemolytic anemia, and 
thrombocytopenia. In recent years, major advances in our understanding of complement-driven 
inherited rare forms of HUS have been achieved. However, in children 90% of cases of HUS are 
associated with a Shiga toxin-producing enteric pathogen. The precise pathological mechanisms in 
this setting are yet to be elucidated. The purpose of this review is to discuss advances in our 
understanding of the pathophysiology underlying HUS and identify the key questions yet to be 
answered by the scientific community. 
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Introduction  
Haemolytic uremic syndrome (HUS) is a major global health care issue as it is the leading 
cause of acute kidney injury in children. It is a triad of acute kidney injury, microangiopathic 
haemolytic anaemia and thrombocytopenia; first described in 1955 by Gasser et al. (1). Over 
ninety percent of childhood HUS cases are associated with infection (2).  Shiga toxin-
producing Escherichia Coli found in contaminated food and water supplies is typically the 
infective trigger; although HUS has also been reported following exposure to Shigella, 
Campylobacter and Streptococcus Pneumoniae (2, 3). In the United States Shiga toxin 
associated HUS affects 0.5-2.1 people per 100,000 population per year. The majority of 
these cases are reported in children under 5 years of age in whom the incidence is 
considerably higher at 6.1 per 100,000 population per year (4).  
The remaining ten percent of HUS cases are termed ‘atypical’. These include familial cases 
which are due to genetic abnormalities in complement regulation and other non-infective 
causes such as pregnancy, drugs, malignancy, connective tissue disorders and 
transplantation (5). Over the last decade there has been a renewed appreciation and 
considerable interest in the role of complement system in renal disease which has been 
compounded by the effectiveness of Eculizumab (a monoclonal humanised antibody against 
C5) in the treatment of atypical HUS.  Since 2009, when Eculizumab was first used in 
atypical HUS, there have been numerous case reports detailing the success of the drug in 
controlling the disease. A landmark prospective Phase 2 trial published in 2013 further 
consolidated the evidence for significant improvement in renal function in atypical HUS 
patients treated with Eculizumab (6, 7).  
The diagnostic challenge for the Nephrologist therefore, is to differentiate between atypical 
HUS and infection associated HUS to facilitate rapid, targeted treatment with Eculizumab if 
indicated. This review will discuss the classification, diagnosis and treatment of HUS; current 
understanding of the pathophysiology underlying the condition and the key questions yet to 
be answered by the scientific community.  
 
  
 
Classification of HUS 
HUS is categorised histopathologically as a thrombotic microangiopathy (TMA).  This term 
was first introduced in 1952 by Symmers to describe: capillary wall thickening, swelling and 
detachment of the endothelial cell from the basement membrane, accumulation of debris in 
the subendothelial space and intraluminal platelet thrombosis; culminating in partial or 
complete obstruction of the vessel (1).  When this process occurs in the microvasculature of 
the kidney (as is the case in HUS) renal impairment is seen due to organ ischaemia. In 
contrast, in thrombotic thrombocytopenic purpura (TTP) neurological impairment is observed 
as the predominant microvascular bed affected is the brain (2). The microangiopathic 
haemolytic anaemia that ensues is a consequence of erythrocyte sheer stress resulting in 
red cell fragmentation. Platelet activation and entrapment in microthrombi as well as 
trafficking to the reticuloendothelial system leads to thrombocytopenia, local thrombosis and 
organ ischaemia (2, 8). Thus, TMA represents a final common pathway in a number of 
disease processes which amongst others include HUS and thrombotic thrombocytopenic 
purpura (TTP). See Figure 1. The clinical sequelae observed is dependent upon the vascular 
bed and organ affected (2). Both conditions are a consequence of endothelial cell injury but 
are now accepted to be different diseases with distinct underlying mechanisms (9). 
TTP is a pentad of microangiopathic haemolytic anaemia, thrombocytopenia, fever, acute 
kidney injury and neurological features (9). It is due to a deficiency in the von Willebrand 
factor cleaving enzyme ADAMTS13 (A Disintegrin and Metalloprotease with 
ThromboSpondin motif repeats 13); or inhibitory autoantibodies (10, 11, 12). Historically, a 
decrease in ADAMTS13 activity has been considered to be specific for a diagnosis of TTP 
(13). However, it is becoming increasingly apparent in recent case reports that reduced 
levels of ADAMTS13 are seen in patients with other forms of TMA including atypical HUS.  
Furthermore, in TTP patients there is evidence of C3 consumption and increased alternative 
complement pathway activation. Work by Noone et al. using ex-vivo models has suggested 
a potential role for von Willebrand factor multimers as complement regulators on the surface 
of endothelial cells (11, 13). Given the overlap in clinical presentation and the emerging 
similarities in possible underlying mechanisms distinguishing between HUS and TTP is 
becoming increasingly challenging for the physician (14). Given the latest advances in 
therapeutic options for atypical HUS and the need for future studies into the treatment of 
TMA it is vital that an accurate diagnosis is made both for the individual patient; but also at a 
population basis to allow appropriate stratification in clinical trials (15).   
 
The Complement Cascade 
The complement system has been implicated in a number of renal diseases and represents 
an area of great interest within the Nephrology community at present (16). It is well 
established that atypical HUS is caused by impaired regulation of complement activation on 
glomerular endothelial cell surfaces (17, 18). Complement hyperactivation following Shiga 
toxin exposure has also been proposed as a mechanism in the development of infection 
associated HUS although this yet to be proven (19). A recent study from Ozaki et al. has 
demonstrated that inhibition of the mannose binding lectin (MBL) complelment pathway 
protected mice against renal injury due to Shiga toxin exposure (20). Hence, it is vital to 
have an understanding of the complement pathway before delving into the pathophysiology 
of HUS. 
The complement pathway forms part of the innate immune response and consists of 60 
proteins which play a vital role in the host defence against pathogens and in the 
maintenance of tissue homeostasis (19, 21). These proteins can be plasmatic (fluid) or 
membrane bound receptors (solid) (2, 22). Three pathways leading to activation of the 
complement cascade have been described: classical, lectin and alternative. All culminate 
with the formation of the membrane attack complex (MAC) leading to the insertion of pores 
in the target cell membrane resulting in osmotic lysis and cell death (19, 23) Figure 2. The 
classical pathway is activated by binding of C1q to antibody-antigen complexes.  The lectin 
pathway is triggered by binding of MBL to mannose containing carbohydrates on microbial 
surfaces which activates MASP 1 (mannan-binding lectin serine protease 1) and MASP 2 
(19, 23). Both the classical and lectin pathways lead to the generation of the same C3 
convertase C4b2a on target cell surfaces resulting in proteolytic cleavage of C3 into C3a and 
C3b (19, 22).  
The alternative pathway differs from the other two in that it is continually active at low levels 
in the plasma. Spontaneous hydrolysis of the thioester bond in C3 induces a conformational 
change in the protein which facilitates binding of complement Factor B. Once bound to C3, 
Factor B is cleaved by Factor D to Ba and Bb. This generates the alternative pathway C3 
convertase C3Bb; resulting in proteolytic cleavage of C3 into C3a and C3b (see Figure 2) 
(19, 22, 23). Association of C3b with C3 convertases (generated by any of the 3 pathways) 
leads to formation of C5 convertases which cleave Factor C5 into C5a and C5b; initiating the 
assembly of the MAC on target cell surfaces (19). This terminal pathway in the complement 
cascade also acts to alert the host defences by the release of chemoattractant and 
inflammatory mediators; C3a and C5a are potent anaphylatoxins that recruit phagocytes and 
induce endothelial cell activation (19, 24).  
The alternative pathway acts as a positive feedback loop – amplifying complement activity. 
C3b on target cell surfaces generated by the classical or lectin pathways acts as a site of 
C3Bb formation and the activation of alternative pathway itself leads to deposits of C3b on 
cell surfaces – further potentiating this loop (23). As such the alternative pathway may 
account for up to 80% terminal pathway activity according to Blatt et al (23). Hence, the 
complement cascade has great potential for non-specific destruction, which host cells must 
be protected from. Indeed, complement activation is regulated by a number of plasma and 
membrane bound factors (19, 22). 
 
Complement Regulation 
It is essential that complement activation is regulated to prevent excessive cell injury and 
inflammation (17, 23). Host cells are protected by surface bound and soluble plasma 
complement regulatory proteins. Of particular importance are the plasma proteins Factor H 
and Factor I which negatively regulate the C3b amplification loop. Although found in the 
plasma both can act in the fluid phase and on cellular surfaces. Their role on cell surfaces 
that lack membrane bound complement regulators e.g. the glomerular basement membrane 
in the kidney is vital as they are the only defence against complement attack and thrombus 
formation (17, 24).  
Notable membrane bound complement factors include CD46 (MCP – membrane co-factor 
protein), CD55 (DAF – decay activating factor), CD59 and CR1. By definition these surface 
bound complement regulatory proteins are restricted in activity by their cellular expression 
and distribution; the exception being CR1 which is expressed by neutrophils, lymphocytes 
and erythrocytes which circulate throughout the body rather than being tissue bound (24, 
25). Atypical HUS is known to be primarily due to hyperactivation of the alternative 
complement pathway as a result of loss of function mutations in complement regulatory 
factors or gain of function mutations in C3 or Factor B (2, 5). Autoantibodies against 
regulatory complement factors have also been described in atypical HUS and with high 
prevalence in haematopoietic stem cell transplantation associated TMA (17). It was the 
discovery by Warwicker et al. in 1998 that a mutation in Factor H led to the development of 
atypical HUS, which prompted the search and subsequent discovery of over 120 mutations 
in complement regulatory genes responsible for atypical HUS (19). It is this link that has 
prompted the investigation of the role of complement in other forms of TMA. 
 
Atypical HUS  
Accounting for ten percent of HUS cases atypical HUS is a rare condition. However, it is 
associated with significant morbidity and mortality; leading to end-stage renal disease in 
around half of patients affected (17). Inheritance may be sporadic, autosomal recessive or 
autosomal dominant with incomplete penetrance (25). Interestingly, identification of the 
specific gene polymorphisms resulting in abnormalities of the complement cascade 
(accounting for up to 70% of atypical HUS cases) provide powerful prognostic information 
allowing patients to be counselled about likelihood of post-transplantation recurrence (5, 19, 
26). Mutations in Complement Factor H are associated with the worst outcomes, whereas 
those with MCP mutations do far better (19). A minority of atypical HUS cases have been 
attributed to the dysfunction in degradation of von Willebrand factor, thrombomodulin 
mutations or loss of function mutations in diacylglycerol kinase ε (DGKε) (26). 
The landmark discovery in 2013 by Lemaire et al. that recessive mutations in DGKε cause 
atypical HUS in a significant proportion of children in the first year of life, has led to an 
alternative pathophysiological mechanism being proposed for the condition (27). Prior to this 
all previous mutations were associated with unrestricted alternative pathway complement 
activation. Diacylglycerol kinases (DGKs) are intracellular lipid kinases that phosphorylate 
diacylglycerol (DAG) to phosphatidic acid (PA) leading to termination of DAG signalling (28). 
The DGKε isoform preferentially phosphorylates arachidonic acid containing DAG (AADAG) 
to PA thereby terminating AADAG signalling (28).  AADAG is a key intracellular signalling 
molecule that activates protein kinase C (PKC). AADAG-dependent PKC signalling promotes 
thrombin-induced platelet activation. In endothelial cells it has been shown to increase 
production of prothrombotic factors such as von Willebrand factor and tissue factor; as well 
as downregulating VEGFR2 signalling, which has been linked to TMAs previously (27, 29). 
Bruneau et al. have demonstrated in endothelial cells that knockdown of DGKε results in a 
proinflammatory and prothrombotic state via over activation of p38 and p44/42 MAP kinases 
(28). Hence, the hypothesis that loss of function mutations in DGKε results in sustained 
AADAG signalling and a subsequent prothrombotic state. See Figure 3.  
In podocytes DAGs have been shown (REF) to modify slit diaphragm function and through 
PKC-dependent pathways downregulate expression of the VEGF receptor VEGFR2 (or Flk-
1). Podocytes are the major source of VEGF which is essential for maintaining the nearby 
glomerular endothelium. Quaggin et al. have shown that disruption of VEGF signalling in 
podocyte-specific VEGFA knock-out mice results in a glomerular TMA with a phenotype that 
recapitulates that seen in HUS. In support of this finding cancer patients treated with the 
VEGF inhibitor bevacizumab have also been reported to develop glomerular TMA (30). 
Although DGKε deficiency was initially thought to cause atypical HUS through mechanisms 
distinct from complement dysregulation; there is mounting evidence that complement 
activation products may alter DGKε regulated pathways in podocytes leading to proteinuria. 
Interestingly, DAG directly activates TRCP6 in the podocyte via a PKC-independent 
mechanism. Mutations leading to hyperactivation of TRPC6 channels are known to result in 
podocyte effacement and inherited forms of nephrotic syndrome (8). Remuzzi et al. have 
reported that proteinuria is more common than initially perceived in atypical HUS. This 
appeared to be more prevalent in children with the condition - although larger numbers of 
cases would need to be reviewed to definitively address this trend. Certainly, glomerular 
epithelial cells could be key in the development of atypical HUS and the interaction of 
complement with the DAG-PKC pathway warrants further investigation (8).  
 
Complement Blockade 
Prior to the advent of the use of Eculizumab a humanised, mouse anti-C5 monoclonal 
antibody; the only treatment option for atypical HUS was plasma exchange and supportive 
therapy in the form of dialysis (31). In contrast to TTP where the response to plasma 
exchange is in the region of 80-90%; atypical HUS patients undergoing plasma exchange 
may see initial improvement in platelet count and anaemia but only transiently; with the 
underlying TMA and complement activation persisting (31, 32). Indeed, end-stage renal 
disease or death occurs in up to 40% of atypical HUS patients at first presentation despite 
plasma exchange (7). Eculizumab has transformed treatment for these patients and is 
increasingly being reported to be efficacious in cases of HUS associated with medications, 
pregnancy and connective tissue disorders such as systemic lupus erythematosus (SLE) 
(33-36). 
Eculizumab binds with high affinity to C5 and blocks the generation of anaphylatoxin C5a 
and the assembly of the MAC (C5b-C9) (7). As such it is a terminal complement pathway 
inhibitor and leaves proximal functions of immune clearance intact (31). The blockade of C5 
however, does increase susceptibility to meningococcal infections. This has prompted the 
recommendation when prescribing Eculizumab, to ensure that patients are vaccinated as 
soon as possible before initiation of treatment. Patients are informed and consented about 
this risk and monitored for the early signs of the infection which can prove fatal (37).  
Following two prospective Phase 2 Trials reported in the NEJM in 2013 by Legendre et al. 
the FDA approved Eculizumab for the treatment of atypical HUS.  These trials included 
patients with atypical HUS aged 12 years and above with thrombocytopenia and renal 
dysfunction (Trial 1); or renal dysfunction alone without a significant reduction in platelet 
count during plasma exchange (Trial 2). Each group received Eculizumab for 26 weeks and 
a subsequent extended period. Both trials demonstrated that Eculizumab treatment inhibited 
complement-mediated TMA and this effect translated clinically to substantial recovery in 
renal function and haematological parameters; with earlier intervention associated with 
greater clinical benefit (7).  
The success of Eculizumab in the treatment of atypical HUS is reflected in expert consensus 
(including NICE approval in the UK – currently the most expensive treatment endorsed by 
this National guidance body); which advocate early use in patients with atypical HUS so as 
to achieve optimal chance of renal recovery (38). See Table 1. The question remains as to 
the necessary duration of Eculizumab treatment for patients with confirmed atypical HUS 
and as to whether its use should be extended to other forms of TMA (39). 
 
Infection Associated HUS 
By far the commonest cause of HUS, infection associated HUS accounts for ninety percent 
of cases (2). Within this group the majority follow exposure to contaminated food and water 
with Shiga toxin producing Escherichia Coli (E.coli) (3). Conventionally this form of HUS has 
been known as ‘typical’ or ‘diarrhoea associated’. However, these terms have proved 
unhelpful given that up to half of patients with atypical HUS can present with an initial 
diarrhoeal illness. This only adds to the complexity of distinguishing between atypical HUS 
and Shiga toxin associated HUS on clinical grounds alone (38). The diagnosis of atypical 
HUS through identification of a mutation in complement regulation by DNA testing is time 
consuming and delays diagnosis. Moreover in up to 50% of cases of atypical HUS no 
predisposing polymorphism is currently detectable (19, 40).  
Given the need for clarity in terminology, the definition STEC HUS is now used to describe 
HUS secondary to Shiga toxin producing Escherichia Coli. This is distinct from other 
infective causes of HUS such as Streptococcal pneumoniae-related HUS which is 
considerably rarer, more severe and due to invasive pneumococcal disease (41). This 
bacteria produces a neuraminidase that exposes the Thomsen-Friedenreich antigen (T-
antigen) normally present on red blood cells, platelets and glomerular endothelial cells in the 
host; thus rendering these cells susceptible to antibody attack resulting in microangiopathic 
haemolytic anaemia, thrombocytopenia and acute kidney injury (41, 42).  
Diagnosis of STEC HUS is reliant upon faecal testing in the laboratory using stool culture, 
immunoassays and PCR (polymerase chain reaction) assay to detect Shiga toxin genes. 
These tests together will identify up to 70% of cases (43). The diagnosis of atypical HUS is 
therefore often implied by the absence of STEC. As a result patients presenting with a 
microangiopathic anaemia, thrombocytopenia and acute kidney injury are commenced on 
plasma exchange. Once TTP has been excluded (ADAMTS 13 activity above 5-10%) and if 
STEC testing is negative then a diagnosis of atypical HUS must be considered likely and 
Eculizumab started (31). 
The pathophysiology underlying STEC HUS is yet to be determined and as such there are 
currently no specific treatments for the disease other than supportive care (20). Acute 
mortality outcomes for STEC HUS have improved with the introduction of early dialysis from 
30% to 5%. However, of those patients that survive the initial insult up to 30% develop 
proteinuria; and 18% will go on to develop chronic renal failure (44). A better understanding 
of the pathophysiology underlying STEC HUS is essential if targeted therapy for this 
condition is to be developed. 
Shiga toxins are exotoxins produced by E. coli, as well as by other bacteria including 
Shigella dysenteriae and Campylobacter jejuni (2, 45). They consist of a single 30 kDa 
enzymatic A subunit in non-covalent association with five identical B subunits of 7 kDa each 
(3, 46). The genes encoding Shiga toxin are found within lambdoid bacteriophages present 
in all pathogenic STEC. Toxin secretion occurs by phage-mediated bacterial lysis. (3, 45). It 
is the B subunit of Shiga toxin that binds to the glycosphingolipid receptor Gb3. It has been 
shown that cells lacking Gb3 expression are resistant to the toxic effects of Shiga toxin; 
meaning the pattern of expression of Gb3 in different cell types is a reliable predictor of 
Shiga toxin site of action (3, 47).  
Unlike human glomerular cells, murine glomerular endothelial cells and podocytes do not 
express Gb3 (47). As a result, development of rodent models of STEC HUS that recapitulate 
the glomerular TMA lesions seen in humans with the disease have not been possible. Mice 
challenged with Shiga toxin alone (orally or intraperitoneally) develop lethal tubular disease 
without histological evidence of glomerular TMA. A mouse model reported by Keepers et al. 
involving administration of both Shiga toxin and lipopolysaccharide was shown to cause 
some evidence of thrombus formation in glomeruli but the predominant lesions were tubular 
and led to dehydration; a phenomenon that is not seen in human disease (48). Clearly, Gb3 
is the cellular target of Shiga toxin and in further support of this Okuda et al. have 
demonstrated constitutive whole body Gb3 knockout mice are completely protected from the 
lethal effect of Shiga toxin exposure (49).  
Following binding to Gb3, Shiga toxin is endocytosed and transported in a retrograde 
manner from the endosome to the trans-Golgi network. From here it is transported to the 
endoplasmic reticulum (ER), where using the ER-associated degradation machinery it is 
able to translocate into host cell cytoplasm (45, 50). Shiga toxin is known to act in three main 
ways: firstly it inactivates ribosomes by enzymatically removing an adenine residue from 28S 
ribosomal RNA. This triggers the ribotoxic stress response leading to MAPK signalling and 
activation of cytokines and chemokines that result in proinflammatory and proapoptotic 
pathways (3, 46). Secondly, the unfolded protein response (UPR) may be triggered by Shiga 
toxin unfolding within the ER. Prolonged signalling via the UPR will induce apoptosis in cells 
(46). Finally, the binding of the B subunit itself can initiate a cytoplasmic transduction 
cascade that is distinct from the ribotoxic stress response but that also culminate in a 
prothrombotic, proinflammatory cellular environment (3, 46, 51). Attempts made to block 
Shiga toxin binding with synthetic Shiga toxin binders such as STARFISH or Synsorb-Pk; or 
to inhibit intracellular transport of the toxin with molecules such as Exo1 and Golgicide A 
have to date been ineffective (45). 
Evidence of complement activation in STEC HUS 
Over the last decade, there has been increasing evidence in support of a role for 
complement activation in Shiga toxin associated HUS. Some patients with STEC HUS have 
been reported to have low levels of circulating C3 and evidence of increased levels of C3 
convertases and Factor B (19).  Furthermore, a recent publication by Ozaki et al. has 
reported a protective effect of a monoclonal antibody against MBL in STEC HUS (20). This 
has led to new insights into the role of complement activation in Shiga toxin induced renal 
injury. However, our understanding of the precise pathophysiological mechanisms 
underlying the disease is far from complete. The literature is divided as to whether C5 
inhibition with Eculizumab is beneficial in STEC HUS (20). This has been complicated by the 
lack of any randomised controlled trials. Attempts at retrospective analysis of patient 
outcomes in outbreaks of STEC HUS such as that seen in Germany in 2011 have been 
made. However, unravelling any meaningful answers as to the effectiveness of Eculizumab 
in such studies is very difficult as only the most severely affected patients that administered 
the treatment and it is unclear as to whether they would have recovered without it (52). 
Further work both in the laboratory and in the clinic is needed to aid our understanding of the 
mechanisms responsible for STEC HUS.  
 
Conclusions 
Complement pathway hyperactivation is emerging as a potential common mechanism 
underlying the pathogenesis of glomerular TMA. Identification of the genetic mutations in 
complement regulatory proteins, C3 convertase components and anti-CFH antibodies in 
atypical HUS has led to the advent of a new era of pharmacological complement modulation 
(19). Indeed, the success of Eculizumab in the management of atypical HUS has 
transformed the management of these patients and resulted in reduced mortality and a 
reduction in progression to end stage renal failure (6).  
Furthermore, support for role of complement in the pathogenesis of secondary HUS is 
provided by recent reports of the efficacy of Eculizumab in the treatment of HUS associated 
with drugs, pregnancy and SLE (33-36). However, the heterogeneity of these groups and the 
discovery that some individuals have an underlying genetic pre-disposition (due to mutations 
in complement regulators) merely adds to the difficulty in determining the true benefit of 
complement blockade in such cases (19). 
The use of Eculizumab in STEC HUS remains controversial and further research is needed 
to elucidate the pathophysiological mechanisms underlying this form of HUS. Delineating the 
role of complement, which pathways are involved and the cellular target of Shiga toxin in the 
glomerulus will be key. The development of a murine model that more accurately 
recapitulates Shiga toxin HUS in the human would mean improved evaluation of any 
potential benefit of complement blockade in the disease prior to clinical trials in humans (53).  
The challenge for the future lies in identifying the particular pathophysiological mechanisms 
responsible for the non-genetic forms of HUS and subsequent development of specific 
treatment strategies for this devastating disease.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
References: 
1. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, haemolytic   
uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 60: 831–  
846, 2001. doi: 10.1046/j.1523-1755.2001. 
2. Keir L, Coward RJM. Advances in our understanding of the pathogenesis of glomerular 
thrombotic microangiopathy. Pediatr Nephrol 26: 523-533, 2011. doi: 10.1007/s00467-010-1637-
4. 
3. Obrig T. Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease. Toxins 2: 2769-
2794, 2010. doi: 10.3390/toxins2122769. 
4. Adams DA, Jajoksy RA, Ajani U, Kriseman J, Sharp P, Onwene DH et al. Summary of 
notifiable diseases United States 2012. MMWR Morb Mortal Wkly Rep. 61(53):1-121, 2014. 
www.cdc.gov/mmwr/mmwr_nd/index.html. 
5. Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic Uraemic Syndrome. Journal of Internal 
Medicine. Oct 2016 [epub ahead of print] doi: 10.1111/joim.12546. 
6. Kavanagh D, Goodship TH, Richards A. Atypical Hemolytic Uremic Syndrome. Semin Nephrol. 
33(6): 508-30, 2013. doi: 10.1016/j.semnephrol.2013.08.003. 
7. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C et al. Terminal 
Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome. N Engl J Med 368: 
2169-81, 2013. doi:10.1056/NEJMoa1208981. 
8. Noris M, Mele C, Remuzzi G. Podocyte dysfunction in atypical haemolytic uraemic syndrome. 
Nature Reviews Nephrology 11: 245-252, 2015. Doi:10.1038/nrneph.2014.250. 
9. Keir LS, Langman CB. Complement and the kidney in the setting of Shiga-toxin haemolytic 
uremic syndrome, organ transplantation and C3 glomerulonephritis. Transfusion and Apheresis 
Science. 54: 203-211, 2016. doi:10.1016/j.transci.2016.04.010. 
10. Tsai HM. Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura. 
Kidney International 112: S11-S14, 2009. doi:10.1038/ki.2008.610. 
11. Noone DG, Riedl M, Pluthero FG, Bowman ML, Liszewski MK, Lu L et al. Von Willebrand 
factor regulates complement on endothelial cells. Kidney International 90: 123-134, 2016. 
doi:10.1016/j.kint2016.03.023. 
12. Tsai HM, Lian ECY. Antibodies to von Willebrand Factor-Cleaving Protease in Acute Thrombotic 
Thrombocytopenic Purpura. N Engl J Med 339: 1585-1594, 1998. doi: 
10.1056/NEJM199811263392203. 
13. Farkas P, Csuka D, Mikes B, Sinkovits G, Reti M, Nemeth E et al. Complement activation, 
inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies. 
Immunobiology 222: 119-127, 2017. doi:org/10.1016/j.imbio.2016.10.014. 
14. Laurence J, Haller H, Mannucci PM, Nangaku M, Parga M, Rodriguez de Cordoba S. 
Atypical haemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin 
Adv Hematol Oncol 11(11): 2-15, 2016. PMID: 27930620 
15. Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J et al. 
Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and 
related thrombotic microangiopathies. J Thromb Haemost 2016. doi:10.111/jth13571 (epub 
ahead of print). 
16. Berger SP, Roos A, Daha MR. Complement and the kidney: What the nephrologist needs to 
know in 2006? Nephrol Dial Transplant 20: 2613-2619, 2005. doi: 10.1093/ndt/gfi166. 
17. Medjeral-Thomas N, Pickering MC. The complement factor H-related proteins. Immunological 
Reviews 274: 191-201, 2016. doi: 10.111/imr.12477. 
18. Westra D, Vernon KA, Volokhina EB, Pickering MC, van de Kar NCAJ, van de Heuvel LP. 
Atypical haemolytic uremic syndrome and genetic aberrations in the complement factor H-related 
5 gene. Journal of Human Genetics 57: 459-464, 2012. doi: 10.1038/jhg.2012.57. 
19. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of 
complement activation. Nat Rev Nephrol 8: 622-633, 2012. doi:10.1038/nrneph.2012.195. 
20. Ozaki M, Kang Y, Tan YS, Pavlov VI, Liu B, Boyle DC et al. Human mannose binding lectin 
inhibitor prevents Shiga toxin-induced renal injury. Kidney International 90: 774-782, 2016. Doi: 
10.1016/jkint.2016.05.011. 
21. Barnum SR. Complement: A Primer for the Coming Therapeutic Revolution. Pharmacol Ther 16: 
30240-6, 2016. doi: 10.1016/j.pharmathera.2016.11.014. 
22. Roumenina LT, Rayes J, Frimat M, Fremeaux-Bacchi V. Endothelial cells:source, barrier and 
target of defensive mediators. Immunological Reviews 274: 307-329, 2016. doi: 
10.1111/imr12479. 
23. Blatt AZ Pathan S, Ferreira VP. Properdin: a tightly regulated critical inflammatory modulator. 
Immunological Reviews 274: 172-190, 2016. doi: 10.1111/imr12466. 
24. Schmidt CQ, Lambris JD, Ricklin D. Protection of host cells by complement regulators. 
Immunological reviews 274: 152-171, 2016. doi: 10.1111/imr12475. 
25. Noris M, Bresin E, Mele C, Remuzzi G. Genetic Atypical Hemolytic-Uremic Syndrome. 
GeneReviews online publication updated 2016. PMID: 20301541. 
26. Durkan AM, Kim S, Craig J, Elliott E. The long-term outcomes of atypical haemolytic uraemic 
syndrome: a national surveillance study. Arch Dis Child 101: 387-391, 2016. doi: 
10.1136/archdischild-2015-309471. 
27. Quaggin SE. DGKE and atypical HUS. Nat Genet 45: 475-476, 2013. doi: 10.1038/ng.2622. 
28. Bruneau S, Neel M, Roumenina LT, Frimat M, Laurent L, Fremeaux-Bacchi V et al. Loss of 
DGKε induces endothelial cell activation and death independently of complement activation.  
Blood 125: 1038-1046, 2015. doi: 10.1182/blood-2104-06-579953. 
29. Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Quintrec M et al. Recessive 
mutations in DGKE cause atypical haemolytic-uremic syndrome. Nat Genet 45: 531-538, 2013. 
doi: 10.1038/ng.2590. 
30. Eremina V, Jefferson JA, Kowalewska J, Hochester H, Haas M, Weisstuch J et al. VEGF 
Inhibition and Renal Thrombotic Microangiopathy. N Engl J Med 358: 1129-1136, 2008. doi: 
10.1056/NEJMoa0707330. 
31. Franchini M. Atypical haemolytic uremic syndrome: from diagnosis to ttreatment. Clin Chem 
Med 53: 1679-1688, 2015. doi:10.1515/cclm-2015-0024. 
32. Clark WF, Huang SH, Walsh MW, Farah M, Hildebrand AM, Sontrop JM. Plasmapheresis for 
the treatment of kidney diseases. Kidney International 90: 974-984, 2016. doi: 
10.1016/j.kint.2016.06.009. 
33. Faguer S, Huart A, Fremeaux-Bacchi V, Ribes D, Chauveau D. Eculizumab and drug-induced 
haemolytic-uraemic syndrome. Clin Kidney J 6: 484-485, 2013. Doi: 10.1093/ckj/sft078. 
34. Mussoni MP, Veneziano FA, Boetti L, Tassi C, Calisesi C, Nucci S et al. Innovative 
therapeutic approach: sequential treatment with plasma exchange and eculizumab in a pregnant 
woman affected by atypical haemolytic-uremic syndrome. Transfus Apher Sci 51(2): 134-136, 
2014. doi: 10.1016/j.transci.2014.08.027. 
35. Saad AF, Roman J, Wyble A, Pacheco LD. Pregnancy-Associated Atypical Hemolytic-Uremic 
Syndrome. AJP Rep. 6(1): e125-128, 2016. doi: 10.1055/s-0036-1579539. 
36. El-Husseini A, Hannan S, Awad A, Jennings S, Cornea V, Sawaya BP. Thrombotic 
microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis 
65(1): 127-130, 2015. Doi: 10.1053/j.ajkd.2014.07.031. 
37. Kaplan BS, Ruebner RL, Spinale JM, Copelovitch L. Current treatment of atypical haemolytic 
uremic syndrome. Intractable and Rare Diseases Research 3(2): 34-45, 2014. doi: 
10.5582/irdr.2014.01001. 
38. Davin JC, Van der Kar NCAJ. Advances and challenges in the management of complement-
mediated thrombotic microangiopathies. Ther Adv Hematol 6(4): 171-185, 2015. doi: 
10.1177/2040620715577613. 
39. Ardissino G, Possenti I, Tel F, Testa S, Salardi S, Ladisa V. Discontinuation of Eculizumab 
treatment in Atypical Hemolytic Uremic Syndrome: An update. Am J Kidney Dis 66(1): 172, 2015. 
doi: 10.1053/j.ajkd.2015.04.010. 
40. Mannucci PM, Cugno M. The complex differential diagnosis between thrombotic 
thrombocytopenic purpura and the atypical hemolytic uremic syndrome: laboratory weapons and 
their impact on treatment choice and monitoring. Thrombosis Research 136: 851-854, 2015. doi: 
10.1016/j.thromres.2015.09.007.  
41. Loupiac A, Elayan A, Cailliez M, Adra AL, Decramer S, Thouret MC et al. Diagnsois of 
Streptococcus pneumoniae-associated haemolytic uremic syndrome. Pediatr Infect Dis J 32(10): 
1045-1049, 2013. doi: 10.1097/INF.0b013e31829ee872. 
42. Szilagyi A, Kiss N, Bereczki C, Talosi G, Racz K, Turi S et al. The role of complement in 
Streptococcus pneumoniae-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 
28(9): 2237-2245, 2013. doi: 10.1093/ndt/gft198. 
43. Wijnsma KL, van Bommel SA, van der Velden T, Volokhina E, Schreuder MF, van den 
Heuvel LP et al. Fecal Daignositics in combination with serology: best test to establish STEC-
HUS.  Pediatr Nephrol 31(11): 2163-2170, 2016. doi: 10.1007/s00467-016-3420-7. 
44. Spinale JM, Ruebner RL, Copelovitch l, Kaplan BS. Long-term outcomes of Shiga toxin 
haemolytic uremic syndrome. Pediatr Nephrol 28(11): 2097-2105, 2013. doi: 10.1007/s00467-
012-2383-6. 
45. Johannes L, Romer W. Shiga toxins – from cell biology to biomedical applications. Nat Rev 
Microbiology 8: 105-116, 2010. doi: 10.1038/nrmicro2279. 
46. Tesh VL. Activation of cell stress response pathways by Shiga Toxins. Cellular Microbiology 
14(1): 1-9, 2012. Doi: 10.1111/j.1462-5822.2011. 
47. Pstoka MA, Obata F, Kolling GL, Gross LK, Saleem MA, Satchell SC et al. Shiga Toxin 2 
Targets the Murine Renal Collecting Duct Epithelium. Infection and Immunity 77: 959-969, 2009. 
doi: 10.1128/IAI.00679-08. 
48. Keepers TR, Pstoka MA, Gross LK, Obrig TG. A murine model of HUS: Shiga toxin with 
lipopolysaccharide mimics that renal damage and physiological response of human disease. J 
Am Soc Nephrol 17: 3404-3414, 2006. doi:  
49. Okuda T, Tokuda N, Numata S, Ito M, Ohta M, Kawamura K et al. Targeted Disruption of 
Gb3/CD77 Synthase Gene resulted in the Complete Deletion of Globo-series Glycosphingolipids 
and Loss of Sensitivity to Verotoxins. J Biol Chem 281: 10230-10235, 2006. Doi: 
10.1074/jbc.M600057200. 
50. Arvidsson I, Stahl A, Hedstrom MM, Kristofferson A, Rylander C, Westman JS et al. Shiga 
Toxin-Induced Complement-Mediated Hemolysis and Release of Complement-Coated Red 
Blood Cell-Derived Microvesicles in Hemolytic Uremic Syndrome. J Immunol 194: 2309-2318, 
2015. doi: 10.4049/jimmunol.1402470. 
51. Betzen C, Plotnicki K, Fathalizadeh F, Pappan K, Fleming T, Bielaszewska M et al. Shiga 
Toxin 2a- Induced Endothelial Injury in Hemolytic Uremic Syndrome: A Metabolomic Analysis. J 
Infect Dis 213: 1031-1040, 2016. doi: 10.1093/infdis/jiv540. 
52. Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J et al. Validation of 
treatment strategies for enterohaemorrhagic Eschericia coli 0104:H4 induced haemolytic uraemic 
syndrome: case control study. 
 
  
 
 
 
Figure 1: Classification of Thrombotic Microangiopathy (TMA). 
It is now widely accepted that classification of TMA according to aetiology (rather than 
clinical features) is a more useful guide to prognosis and treatment. TMA represents a final 
common pathway in many disease processes (2).  
 
 
 
 
PLTs – platelets; HUS – Haemolytic uremic syndrome; AKI – acute kidney injury; CNI – calcineurin 
inhibitors; SLE – systemic lupus erythematosus; APLS – anti-phospholipid syndrome. 
  
Figure 2: The Complement Cascade. 
Three pathways have been described leading to activation of the complement pathway; 
classical, lectin and alternative. All culminate with the formation of the membrane attack 
complex (MAC) leading to the insertion of pores into the target cell membrane resulting in 
osmotic lysis and cell death. The alternative pathway differs from the other two in that it is 
continually active at low levels in the plasma and is activated by spontaneous hydrolysis of a 
thioester bond in C3. To protect host cells from non-specific destruction complement 
activation is regulated by a number of plasma (CFH, CFI) and membrane bound factors (19, 
22, 23).  
 
 
 
 
  
Figure 3: The effect of AADAG signalling. 
DGKε is an intracellular kinase that preferentially phosphorylates AADAG to PA thereby 
terminating AADAG signalling. Loss of function mutations in DGKε lead to unregulated 
AADAG signalling and PKC dependent platelet activation and increased production of pro-
thrombotic factors (27, 28, 29).  
 
 
 
  
Table 1: Diagnosis and Management of Thrombotic Microangiopathies (TMAs). 
 
 
Type of TMA 
 
 
Diagnosis 
 
Management 
 
TTP 
 
 
 
Pentad of clinical symptoms 
(thrombocytopenia, haemolytic anaemia, 
AKI, fever and neurological features). 
 
ADAMTS13 <10% 
 
 
Plasma Exchange (PEX) 
Steroids  
Consider Rituximab 
 
 
Infective HUS 
 
(STEC, Shigella, 
Campylobacter HUS; 
Pneumococcal HUS) 
 
 
Triad of thrombocytopenia, haemolytic 
anaemia and AKI). 
 
Stool culture 
Positive Serology  
 
ADAMTS13 >10%  
 
 
Supportive – may require 
renal replacement 
therapy. 
 
Atypical HUS 
 
 
Triad of thrombocytopenia, haemolytic 
anaemia and AKI). 
 
Measurement of complement regulatory 
factors (CFH, CFI and MCP) and C3/C4. 
 
Genetic Screening for complement 
mutations. 
 
ADAMTS13 >10%  
 
Stool culture and serology negative and 
infective cause not suspected. 
 
 
PEX 
Eculizumab 
 
Consider steroids if anti-
Factor H autoantibodies 
present. 
 
Transplantation 
 
 
Prophylaxis in known atypical HUS 
mutations 
 
De novo atypical HUS  
 
 
PEX 
Eculizumab 
 
Rituximab to be 
considered if 
autoantibodies to Factor 
H present. 
 
In CFH mutations 
consider combined liver 
– kidney transplantation. 
 
 
 
